Prototype project for antibody to develop and deploy a comprehensive, ultra high throughput monoclonal antibody discovery and engineering platform, antibody accelerated engineering by a universal…
Other Transaction IDV Awarded Last action
- Contract number
- W911SR2490002
- Awardee
-
The Methodist Hospital Research Institute UEI XJUCJAYJWYV1 Part of Universal Health Services, Inc.
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Task orders
- 0
Award facts
- Last date to order
- Not on record
- IDV ceiling
- $10,529,216.00
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
Award details come from SAM.gov/FPDS.
About this IDV
Joint PEO Chemical and Biological Defense awarded an Other Transaction IDV to The Methodist Hospital Research Institute on October 13, 2023, with a ceiling of $10.5 million to develop and deploy a comprehensive, ultra-high-throughput monoclonal antibody discovery and engineering platform (ANTAEUS) selected via broad agency announcement. The Methodist Hospital Research Institute, a nonprofit biomedical research organization within the Texas Medical Center in Houston, brings translational immunology and T-cell engineering capability to the effort, with core strength in mRNA vaccine platforms, CAR-T cell optimization, and specialized molecular and cellular analytics infrastructure including flow cytometry, mass cytometry, and transcriptomics cores. Work is performed at The Methodist Hospital Research Institute's primary location (6565 Fannin Street, Houston, Texas) and affiliated Methodist hospitals in the greater Houston area including Willowbrook, Sugarland, San Jacinto, and West Houston. The prototype project supports monoclonal antibody discovery and engineering as part of the Joint PEO Chemical and Biological Defense's broader defense technology development portfolio.
Description
Prototype project for antibody to develop and deploy a comprehensive, ultra high throughput monoclonal antibody discovery and engineering platform, antibody accelerated engineering by a universal selection (antaeus) selected via BAA.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | $500,000 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $500,000 | |
| Funding Only Action | -$500,000 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $500,000 | |
| Funding Only Action | $1,208 | |
| Funding Only Action | $2,000,000 | |
| Original award | $627,546 |
Quick answers
Who was awarded contract W911SR2490002?
W911SR2490002 was awarded to The Methodist Hospital Research Institute by ACC Aberdeen Proving Ground (Army Contracting Command) on October 13, 2023.
How much is contract W911SR2490002 worth?
W911SR2490002's own ceiling is $10,529,216.
Which agency awarded contract W911SR2490002?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR2490002, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911SR2490002 competed?
The extent of competition for W911SR2490002 was competed.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV